C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/863 (2006.01) A61K 39/12 (2006.01) A61K 39/275 (2006.01) A61K 48/00 (2006.01) A61P 31/12 (2006.01) C12N 7/01 (2006.01) C12N 7/04 (2006.01) C12P 21/02 (2006.01)
Patent
CA 2558659
What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant canary poxvirus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
Audonnet Jean-Christophe F.
Cox William I.
de Taisne Charles
Gettig Russell Robert
Johnson Gerard P.
Connaught Technology Corporation
Smart & Biggar
LandOfFree
Genetically engineered canary poxvirus-based vaccine strain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetically engineered canary poxvirus-based vaccine strain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically engineered canary poxvirus-based vaccine strain will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1450829